Phase IIb trial of oral ezatiostat in patients with low to intermediate-1 risk, transfusion dependent, non-deletion 5q myelodysplastic syndromes.

Trial Profile

Phase IIb trial of oral ezatiostat in patients with low to intermediate-1 risk, transfusion dependent, non-deletion 5q myelodysplastic syndromes.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2013

At a glance

  • Drugs Ezatiostat (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2013 In order to focus its resources on the registrational programme, Telik has decided to stop further enrollment it its phase II exploratory trials, including this trial, as announced in a company media release.
    • 22 Jan 2013 Status changed from recruiting to active, no longer recruiting based on information reported in a Telik media release.
    • 08 Aug 2012 New source identified and integrated (Vanderbilt-Ingram Cancer Center; VICCHEM1208).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top